1. II Medical Department, ``Coburg`` Regional Clinic, University of Wuerzburg, Coburg, Germany.
2. Pulmonary Department-Oncology Unit, ``G. Papanikolaou`` General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
J Cancer. 2014 Mar 24;5(5):344-50. doi: 10.7150/jca.9021. eCollection 2014.
Inhaled therapy for lung cancer is a local form of treatment. Currently inhaled non-specific cytotoxic agents have been evaluated as a future treatment for local disease control and distant metastasis control. There are few information regarding the influence of local transporters and gene expression of the respiratory epithelium to the absorption of administered drugs. In the current work we used adenoviral-type 5(dE1/E3) (Cytomegalovirus promoter) with human ABCA10 transgene (Ad-h-ABCA10) purchased from Vector Labs(®) in order to investigate whether gene therapy can be used as a pre-treatment to enhance the efficiency of inhaled cisplatin. We included the following groups to our work: a) control, b) aerosol vector, c) aerosol vector plus cisplatin, d) aerosol cisplatin, e) intratumoral cisplatin administration, f) intratumoral vector plus cisplatin administration. The results indicate that the aerosol cisplatin group had a long term survival with the intratumoral cisplatin group following. The enhancement of the ABCA family locally to the respiratory system prior to the aerosol cisplatin administration can be used safely and efficiently. Future treatment design of local therapies should include the investigation of local transporters and genes.
肺癌吸入治疗是一种局部治疗形式。目前，吸入非特异性细胞毒性药物已被评估为局部疾病控制和远处转移控制的未来治疗方法。关于局部转运体和呼吸上皮细胞的基因表达对给予药物吸收的影响的信息很少。在目前的工作中，我们使用了腺病毒 5 型（dE1/E3）（巨细胞病毒启动子）与从 Vector Labs（®）购买的人 ABCA10 转基因（Ad-h-ABCA10），以研究基因治疗是否可作为预处理以提高吸入顺铂的效率。我们将以下组纳入我们的工作：a）对照组，b）气雾剂载体，c）气雾剂载体加顺铂，d）气雾剂顺铂，e）肿瘤内顺铂给药，f）肿瘤内载体加顺铂给药。结果表明，气雾剂顺铂组的长期存活率高于肿瘤内顺铂组。在给予气雾剂顺铂之前，局部 ABCA 家族向呼吸系统的增强可以安全有效地使用。局部治疗的未来治疗设计应包括对局部转运体和基因的研究。
